Medtronic has announced US Food and Drug Administration (FDA) approval to conduct an early feasibility study using the Affera Mapping and Ablation System for sustained VT, a serious heart condition.

The 2024 edition of Transcatheter Cardiovascular Therapeutics (TCT) once again highlighted significant innovations in ...

Medtronic announced new long-term data from the SPYRAL HTN-ON MED clinical trial of the company’s Symplicity Spyral renal ...

The Sphere-9 catheter (Medtronic) Medtronic said its ... heart tissue has been scarred from a previous heart attack. “Currently approved treatments for VT involve only RF energy and require ...

Johnson & Johnson MedTech will enter the U.S. pulsed field ablation market following an FDA green light for its Varipulse ...

Medtronic plc has announced United States Food and Drug Administration (FDA) approval of the Affera Mapping and Ablation ...

The three medtech firms unveiled new data this week during TCT 2024 in Washington, D.C. Here’s what the results mean for the ...

J&J is the third medtech company to gain U.S. approval for pulsed field ablation, a new atrial fibrillation treatment seeing rapid adoption.

Pacemakers send electrical pulses to regulate a person’s heart rate and ... vice president of Medtronic’s cardiac pacing therapies. The blackout was front page news even before the child ...

Medtronic announced results from two studies evaluating the utility of atherectomy for peripheral endovascular interventions.

their families and societies of improving access to timely stroke diagnosis and treatment. Philips and Medtronic Neurovascular also further expanded and strengthened their partnerships with the World ...

their families and societies of improving access to timely stroke diagnosis and treatment. Philips and Medtronic Neurovascular also further expanded and strengthened their partnerships with the ...